{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Mamot C"],"pubmed_abstract":["Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis is poor and more than three quarters of patients experience progression 12 months after the initiation of conventional first-line chemotherapy. Approximately two thirds of TNBC express epidermal growth factor receptor 1 (EGFR). We have developed an anti-EGFR targeted nanocontainer drug by inserting anti-EGFR antibody fragments into the membrane of pegylated liposomes (anti-EGFR-ILs-dox). The payload consists of doxorubicin, a standard drug for TNBC. In a first-in-human phase I trial in 26 patients with various advanced solid malignancies, anti-EGFR-ILs-dox has shown little toxicity and encouraging efficacy. In this single-arm phase II trial, we assessed the efficacy of anti-"],"journal":["Scientific reports"],"pagination":["3705"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9988854"],"repository":["biostudies-literature"],"pubmed_title":["A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer."],"pmcid":["PMC9988854"],"pubmed_authors":["Wicki A","Bartschi D","Caspar CB","Dedes KJ","von Moos R","Novak U","Li Q","Membrez-Antonioli V","Winterhalder R","Riniker S","Tzankov A","Hasler-Strub U","Obermann EC","Rochlitz C","Bodmer A","Holer L","Boos LA","Ackermann C","Deuster S","Zaman K","Senn M","Mamot C","Zurrer-Hardi U","Ritschard R"],"additional_accession":[]},"is_claimable":false,"name":"A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.","description":"Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis is poor and more than three quarters of patients experience progression 12 months after the initiation of conventional first-line chemotherapy. Approximately two thirds of TNBC express epidermal growth factor receptor 1 (EGFR). We have developed an anti-EGFR targeted nanocontainer drug by inserting anti-EGFR antibody fragments into the membrane of pegylated liposomes (anti-EGFR-ILs-dox). The payload consists of doxorubicin, a standard drug for TNBC. In a first-in-human phase I trial in 26 patients with various advanced solid malignancies, anti-EGFR-ILs-dox has shown little toxicity and encouraging efficacy. In this single-arm phase II trial, we assessed the efficacy of anti-","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-19T02:37:55.391Z","creation":"2025-02-19T04:43:48.447Z"},"accession":"S-EPMC9988854","cross_references":{"pubmed":["36879012"],"doi":["10.1038/s41598-023-30950-z"]}}